

15-16 DEC, 2023

Precision Cancer
Screening with
Al Perspectives

TOKYO, JAPAN
Hotel Villa Fontaine Grand Tokyo-Ariake

# IACCS, Breast/Cervical /Lung /Oral Cancer Sessions

Room 1 & 2

•	Program	3
<b>•</b>	Breast Cancer-Keynote Speech	6
<b>•</b>	Cervical Cancer-Keynote Speech	11
<b>•</b>	Special Speech	17
<b>•</b>	Poster Exhibition	23
<b>•</b>	Lung Cancer-Keynote Speech	24
<b>•</b>	Oral Cancer-Keynote Speech	33
<b>♦</b>	Poster Award & Closing Remarks	40





10:20-11:20

11:20-12:20

# IACCS, Breast/Cervical /Lung /Oral Cancer Sessions

Room 1 & 2

Bellesalle Ariake Conference Center 4F, Hotel Villa Fontaine Grand Tokyo Ariake

Prof.

Time Topic Speaker Moderator

#### **Breast Cancer**

Chair: Prof. Noriaki Ohuchi Co-Chair: Prof. King-Jen Chang

#### **Keynote Speech**

**Breast Cancer Screening:** 

A randomized controlled trial to *Prof.* 

evaluate adjunctive ultrasonography Noriaki Ohuchi King-Jen Chang

for women aged 40-49, J-START

(30 min)

**Discussant:** Prof. Chiun-Sheng Huang, Taiwan Young Women Breast Cancer

Screening Trial (10 min)

Panelist: Prof. Noriaki Ohuchi/ Prof. King-Jen Chang/ Prof. Chiun-Sheng Huang

#### **Cervical Cancer**

Chair: Dr. Philip Castle Co-Chair: Prof. Chiung-Ru Lai

**Keynote Speech** 

State-of-the-art Cervical Cancer

Dr. Prof.

State-of-the-art Cervical Cancer Philip Castle Chiung-Ru Lai

Prevention (30 min)

Discussant: Prof. Chiung-Ru Lai, Taiwan Experience of Cervical Cancer Screening

(10 min)

Panelist: Dr. Philip Castle/Prof. Chiung-Ru Lai/Dr. Mathuros Tipayamongkholgul

#### Lunch





# IACCS, Breast/Cervical /Lung /Oral Cancer Sessions

Room 1 & 2

П

Bellesalle Ariake Conference Center 4F, Hotel Villa Fontaine Grand Tokyo Ariake

Time	Торіс	Speaker	Moderator
	Special Speech Breast Cancer Screening in Asia: Research and NGO Viewpoint		
12:20-12:35	Breast Cancer Screening in Hong Kong (HKBCF)	Dr. Wai-Ka Hung	Dr. Hsien Tang Yeh
12:35-12:50	Breast Cancer Screening in Thailand	Dr. Pongdech Sarakarn	
12:50-13:05	Breast Cancer Screening in Taiwan	Dr. Wen-Hung Kuo	Prof.
13:05-13:20	Taiwan Breast Cancer Foundation	Director Ai-Jen Tsai	Robert Smith
13:20-14:10	Poster Exhibition 3. Breast Cancer Screening 4. Cervical Cancer Screening 5. Oral Cancer Prevention 6. Lung Cancer Screening		Room 7





# IACCS, Breast/Cervical /Lung /Oral Cancer Sessions

Room 1 & 2

Ш

Bellesalle Ariake Conference Center 4F, Hotel Villa Fontaine Grand Tokyo Ariake

1111			
Time	Topic	Speaker	Moderator
	<b>Keynote Speech</b> Precision LDCT Screening in Asia (20 min)	Prof. Chisato Hamashima	
14:10-15:10	<b>Keynote Speech</b> Individualized Risk Prediction for Target Expansion of Lung Cancer Screening (20 min)	Prof. Yeol Kim	Prof. Yeun-Chung Chang
	<b>Panelist:</b> Prof. Kai-Jen Chuang/ Prof. Chisato Hamashima/ Prof. Yeol Kim/ Prof. Yeun-Chung Chang		
15:10-15:25	:10-15:25 Coffee Break		Room4
Oral Cancer			

Chair: Dr. Anil Chaturvedi Co-Chair: Prof. Ching-Yu Yen

Precision Prevention of Oral Cancer (30 min)	Dr. Anil Chaturvedi	Prof. Ching-Yu Yen
Discussant:		

15:25-16:35


Prof. Malliga J Subramanian, Oral Cancer Screening in India (10 min)

Dr. Kishore Kumar Pradhananga, Oral Cancer Screening in Nepal (10 min)

Panelist:

Dr. Anil Chaturvedi/ Prof. Ching-Yu Yen/ Dr. Kelly Yu/ Prof. Malliga J Subramanian/ Dr. Kishore Kumar Pradhananga







Noriaki Ohuchi Tohoku University

- Graduated from Tohoku University in 1978 and earned a PhD degree in 1984.
- Served as a fellow at the Laboratory of Tumor Immunology and Biology, National Cancer Institute, NIH, USA, starting in 1984.
- Appointed as a professor at Tohoku University in 1999.
- Held the position of Dean of the Graduate School of Medicine, Tohoku University, from 2012 to 2015.
- Currently serves as the Chair of the National Committee on Cancer Screening, Japan, since 2012.
- Research expertise spans multiple fields, including oncology, surgery, molecular biology, and cancer screening.
- Notable project: Led the Japan Strategic Anti-cancer Randomized Trial (J-START), supported by MHLW from 2007 to 2014 and by AMED from 2015 to the present.
- Achieved a significant milestone when the primary endpoint assessing the efficacy of adjunctive ultrasonography in improving the sensitivity and detection rate of early breast cancer was published in The Lancet in 2016.
- Further contributed to the field with a sub-analysis evaluating adjunctive ultrasonography for breast cancer screening among women aged 40-49 with varying breast density, published in JAMA Network Open in 2021.



King-Jen Chang National Taiwan University Hospital

- Founder and the first president of Taiwan Breast Cancer Society
- Founder and the first president of the Taiwan Breast Cancer Foundation (TBCF)
- Ex-Chairman, Department of Surgery, College of Medicine, National Taiwan University Hospital
- Ex-professor of Surgery Department, College of Medicine, National Taiwan University Hospital
- Professor Emeritus, College of Medicine, National Taiwan University
- Ex-superintendent, Taoyuan General Hospital, Ministry of Health and Welfare
- Support the implementation of population-based breast cancer screening in Taiwan
- Currently serves as the visiting staff of Department of Surgery at National Taiwan University Hospital in Taipei, Taiwan
- Specializes in research related to the clinical applications of functional ultrasound imaging for breast diagnosis





## Breast Cancer - Keynote Speech

Breast Cancer Screening: A randomized controlled trial to evaluate adjunctive ultrasonography for women aged 40-49, J-START









## Breast Cancer - Discussant

#### Taiwan Young Women Breast Cancer Screening Trial



Prof. Chiun-Sheng Huang National Taiwan University Hospital



Prof. Noriaki Ohuchi
Tohoku University



Prof. King-Jen Chang National Taiwan University Hospital

IACCS, Breast/Cervical /Lung /Oral Cancer International Asian Cancer and Chronic Disease Screening Network, IACCS 2023



## **Breast Cancer - Panelist**



Prof. Noriaki Ohuchi
Tohoku University



Prof. King-Jen Chang National Taiwan University Hospital



Prof. Chiun-Sheng Huang
National Taiwan University Hospital





**Chiun-Sheng Huang National Taiwan University** Hospital

- Attending Physician, Department of Surgery, National Taiwan University Hospital
- Director, Breast Medical Center, National Taiwan University Hospital





Philip Castle
Division of Cancer Prevention,
National Cancer Institute

- Director of the Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI) since July 2020
- Oversees cancer prevention, early detection, screening, and symptom/toxicity management research
- Leads NCI Cancer Prevention Fellowship Program (CPFP)
- Ph.D. in Biophysics and MPH from The Johns Hopkins University
- Tenured professor at Albert Einstein College of Medicine
- Former Chief Scientific Officer of the American Society for Clinical Pathology
- Principal investigator for over 15 years, conducting global epidemiologic research
  - Co-authored 400+ articles on HPV, cervical/anogenital cancers, and related research
- Recipient of NCI Cancer Prevention Fellowship Distinguished Alumnus and Arthur S. Flemming Award
  - Senior investigator with NCI's Division of Cancer Epidemiology and Genetics
  - Focuses on cancer prevention technologies, health disparities, screening, and international health research
- Active studies in Mozambique, Rwanda, India, and with Kaiser Permanente Northern California



Chiung-Ru Lai
Taipei Veterans General Hospital

#### **Affiliations**

The physician of the Taipei Veterans General Hospital

#### **Education**

Bachelor of National Yang-Ming Medical University

#### Experience

- Attending pathologist, Department of Pathology & Laboratory Medicine, Taipei Veterans General Hospital
- Section Chief, Cytopathology, Taipei Veterans General Hospital
- Resident, Department of Pathology, Taipei Veterans General Hospital
- Visiting Staff, Department of Pathology, Taipei Veterans General Hospital






### **State-of-the-art Cervical Cancer Prevention**

Dr. Philip Castle

Division of Cancer Prevention, National Cancer Institute

The discovery that human papillomavirus (HPV) is the necessary but uncommon cause of cervical cancer has transformed its prevention. Prophylactic HPV vaccination is highly effective in preventing invasive cervical cancer, especially when given to young women before they have started having sex. Because of its much greater sensitivity and reliability, HPV testing has replaced Pap testing as the standard-of-care for cervical cancer screening. However, there are critical gaps in our global strategy for cervical cancer control, which include (but limited to): 1) condom use has not been sufficiently emphasized as a method of primary prevention against HPV; 2) there is a limited global procurement strategy, like GAVI for vaccines to the lowestincome countries, to provide affordable vaccination to GAVI-ineligible lower-income countries. Moreover, Gardasil® 9 is not currently available through GAVI; 3) there is no global procurement strategy for in vitro diagnostics, which would not only catalyze HPV-based screening but increase the capacity to the control of other cancers and non-communicable diseases; 4) primary and secondary prevention in women living with HIV has not been optimized; 5) there is no highly effective biological therapeutic agent against chronic HPV infection and related abnormalities; and 6) in light of the possible increase in screen-detected invasive cervical cancers, there is a great need to increase global capacity to treat cervical cancer. Without implementing a comprehensive strategy, significant progress in cervical cancer control is unlikely to be realized in the 21st century. IF we cannot overcome the current barriers to achieve global cervical cancer control, the "low-hanging" fruit", what chance do we have to control other, more recalcitrant cancers globally?







IACCS, Breast/Cervical /Lung /Oral Cancer International Asian Cancer and Chronic Disease Screening Network, IACCS 2023

Prof. Chiung-Ru Lai

Taipei Veterans General Hospital

Dr. Philip Castle

National Cancer Institute

Dr. Mathuros

Tipayamongkholgul Mahidol University



## Special Speech

Breast Cancer Screening in Asia: Research and NGO Viewpoint

### Breast Cancer Screening in Hong Kong (HKBCF)



Dr. Wai-Ka Hung Hong Kong Breast Cancer Foundation



IACCS, Breast/Cervical /Lung /Oral Cancer
International Asian Cancer and Chronic Disease Screening Network, IACCS 2023



## Special Speech

Breast Cancer Screening in Asia: Research and NGO Viewpoint

### **Breast Cancer Screening in Thailand**



**Dr. Pongdech Sarakarn** *Khon Kaen University (Thailand)* 







Yeh, Hsien-Tang **Lotung Poh-Ai Hospital** 

- Lo-Hsu medical foundation, Lotung Poh-Ai hospital
- MD, school of medicine, China Medical University, Taiwan
- Chief resident, depart of surgery, National Taiwan University Hospital
- Chief, department of surgery, Lotung Poh-Ai hospital
- Chair, Cancer screening working group, Lotung Poh-Ai hospital
- Director, Cancer committee, Lotung Poh-Ai hospital
- Chief Deputy superintendent, Lotung Poh-Ai hospital
- Evaluation committee member, National cancer certification program
- Evaluation committee member, Breast cancer disease specific certification program
- Director, Taiwan Breast Cancer Society
- Director, Taiwan Oncoplastic Breast Surgery Society





Wai-Ka Hung
Hong Kong Breast Cancer
Foundation

- Graduated with Distinction in Surgery from the University of Hong Kong in 1991, earning awards such as the Digby Memorial Medal, Nesta & John Gray Gold Medal in Surgery, and the Chan Kai Ming Prize.
- Extensive surgical training at Queen Mary Hospital and Kwong Wah Hospital.
- Further specialized in Breast Surgery with training under Professor Michael Baum at the University College London and Professor Robert Mansel at Cardiff, UK in 1999.
- Expertise in Minimally Invasive Breast Surgery.
- Awarded the GB Ong Travelling Fellowship in 2009 for advanced training in Tokyo and Shanghai.
- Earned a Master of Surgery degree from the University of Hong Kong in 2012 with a thesis on the "Application of the Sentinel node concept in Breast Cancer Surgery."
- Private practice since 2010.
- Editorial board member of the Hong Kong Medical Journal.
- Council Member of the Hong Kong Society of Breast Surgeons.
- Dedicated to promoting breast health and cancer screening as an Honorary Consultant of the Well Women Clinics of the Tung Wah Groups of Hospitals.
- Involved in the operations of the Breast Health Centre (BHC) of the Hong Kong Breast Cancer Foundation (HKBCF) since its inception in 2011.
- Council member of the HKBCF since 2015.
- Chairman of the BHC Advisory Committee, overseeing BHC operations since 2017.



Pongdech Sarakarn
Khon Kaen University

- Associate Professor at Faculty of Public Health Khon-Kaen University
- ASEAN Cancer Epidemiology and Prevention Research Group
- Principal investigator, population-based colorectal cancer screening program in Nam-pong, Khon-Kaen, Thailand



## Special Speech

Breast Cancer Screening in Asia: Research and NGO Viewpoint

### Breast Cancer Screening in Taiwan



KUO, Wen-Hung
National Taiwan University Hospital



IACCS, Breast/Cervical /Lung /Oral Cancer International Asian Cancer and Chronic Disease Screening Network, IACCS 2023



## Special Speech

Breast Cancer Screening in Asia: Research and NGO Viewpoint

#### **Taiwan Breast Cancer Foundation**



Director Ai-Jen Tsai
Taiwan Breast Cancer Foundation







**Robert Smith American Cancer Society** 

- Cancer epidemiologist and Senior VP, Cancer Screening, and Director, ACS Center for Cancer Screening at ACS, Atlanta, Georgia, U.S.
- Adjunct Professor of Epidemiology at Emory University and Honorary Professor at Queen Mary University of London.
- Research interests: cancer epidemiology, prevention programs, health service quality, and survivorship.
- PhD from State University of New York at Stony Brook (1983).
- Previous positions at Boston University School of Public Health and Centers for Disease Control.
- Leads ACS in developing cancer screening guidelines and policy projects.
- Author of 400+ peer-reviewed publications and frequent lecturer on cancer screening.
- Serves on national and international advisory committees.
- Founding member of American Cancer Society's National Colorectal Cancer Roundtable and National Lung Cancer Roundtable.
- Honored with awards, including Cancer Prevention Laurel and Medal of Honor from IARC.



Wen-Hung Kuo National Taiwan University Hospital

#### Affiliations

- Clinical associate professor, Department of Surgery, National Taiwan University, School of Medicine
- Visiting staff, Department of Surgery, National Taiwan University Hospital

#### Education

- Ph.D., College of Medicine Graduate institute of Clinical Medicine, National Taiwan University
- M.D., College of Medicine, National Taiwan University

#### Experience

- 2011/02-2014/07 Clinical assistant professor, Department of Surgery, National Taiwan University, School of Medicine
- 2009/08-2011/02 Adjunct assistant professor, Department of Surgery, National Taiwan University, School of Medicine
- 1997/07-1998/07 Research fellow, Department of Surgery, National Taiwan University Hospital
- 1996/07-1997/06 Chief resident, Department of Surgery, National Taiwan University Hospital
- 1992/07-1996/06 Resident, Department of Surgery, National Taiwan University Hospital



Ai-Jen Tsai
Taiwan Breast Cancer
Foundation

#### Affiliations

- General Director, Taiwan Breast Cancer Foundation
- Education
  - College of Medicine Taipei Medical University
- Experience
  - General Director, Taiwan Breast Cancer Foundation
  - Dept. of Biochemistry College of Medicine National Taiwan University



## **Poster Exhibition**

- Breast Cancer Screening
- Cervical Cancer Screening
- Oral Cancer Prevention
- Lung Cancer Screening





IACCS, Breast/Cervical /Lung /Oral Cancer International Asian Cancer and Chronic Disease Screening Network, IACCS 2023

**Prof. Chisato Hamashima** 

Teikyo University



Prof. Yeun-Chung Chang
National Taiwan University Hospital



**Chisato Hamashima Teikyo University** 

- Professor, Health Policy Research Section, Division of Nursing Faculty of Medical Technology, Teikyo University (Tokyo, Japan)
- Visiting Researcher, Center for Cancer Control National Cancer Center of Japan (Tokyo, Japan)



Yeun-Chung Chang National Taiwan University

- Professor of Radiology at National Taiwan University College of Medicine (NTUCM).
- Residency in Radiology at National Taiwan University Hospital (NTUH).
- Staff radiologist position since 1980 after receiving a complete residency in radiology at National Taiwan University Hospital (NTUH).
- Trained as a chest radiology fellow at Duke University Medical Center (1994-1995).
- Expertise in cardiothoracic and breast imaging.
- Ph.D. in Electrical Engineering from National Taiwan University (2004), specializing in dynamic contrast-enhanced magnetic resonance for breast cancer.
- Pioneered CT-guided core biopsy of lung lesions since 1996 and CT-guided localization for VATS since 2009 at NTUH.
- Chief of the Cardiopulmonary Section in the Department of Medical Imaging at NTUH since 2005.
- Former Director of the Department of Medical Imaging at NTUH (2014-2020).
- Research interests include cardiovascular imaging, lung and breast cancer imaging, percutaneous chest and breast interventions, CT, MRI, and multimodality imaging.
- Elected as a Fleischner Society Member in 2014.
- Former Board Member and President of the Taiwan Radiological Society (TRS) (2013-2019).
- Served as Congress President of the Asian Society of Cardiovascular Imaging (ASCI) in 2019.
- Founding member and Secretary General of the Asian Society of Thoracic Radiology (ASTR) (2016-2019).
- Holds various leadership roles in academic societies, including Executive Board Member of TRS and ASCI, and constitution committee member of the Asian-Oceanian Society of Radiology (AOSR).
- Leads multidisciplinary projects such as AI platform development for chest CT and research on monitoring therapeutic responses in lung cancer through computer-aided quantification and multimodality imaging.
- Actively involved in clinical trials related to lung and breast cancer.





## Lung Cancer - Keynote Speech

## Precision LDCT Screening in Asia



Prof. Chisato Hamashima

Teikyo University





## **Precision LDCT Screening in Asia**

Chisato Hamashima Teikyo University

**Basic concept:** Precision medicine is defined as medicine that offers a highly accurate diagnosis and treatment based on individual risks. It involves smart screening using extensive databases, risk stratification, and artificial intelligence. It has also been adopted as an actual method to improve health outcomes.

**Background:** Lung cancer has been a heavy burden worldwide, and an efficient screening program has been required. Low-dose CT (LDCT) screening was evaluated to reduce mortality from lung cancer based on results of the NLST and NELSON studies, and some countries have introduced it. Although LDCT screening has targeted current and ex-smokers, chest X-ray screening for individuals with averagerisk individuals, including never-smokers, has been performed in Japan.

Asian perspective: As a result of the decrease in smoking rate, the primary histology of lung cancer has changed from squamous carcinoma to adenocarcinoma. Since adenocarcinoma has been common among never-smokers in East Asian countries, we should reconsider the target group for LDCT screening. An RCT for LDCT screening has been performed for the average-risk population in Japan. However, if never-smokers are included as targets for LDCT screening, unnecessary radiation exposure could become a harm. The balance of benefits and harm should be considered in LDCT screening for never smokers. Risk stratification could be a solution that focuses on high-risk groups based on ethnic differences. The model for targeting high-risk groups was developed in the UK study and adopted in the Liverpool study. For the development of an East Asian model for selecting an appropriate target for LDCT screening, the IACCS collaboration should be required.





## Lung Cancer - Keynote Speech

Individualized Risk Prediction for Target Expansion of Lung Cancer Screening



Prof. Yeol Kim
National Cancer Center



Prof. Yeun-Chung Chang
National Taiwan University Hospital





**Yeol Kim National Cancer Center, Korea** 

- Professor, Department of Cancer Control, Graduate School of Cancer Science and Policy (GCSP), National Cancer Center, Korea.
- Head of Center for Quality Control of Korean National Lung Cancer Screening Program.
- Head, Center for Tobacco Control, National Cancer Center
- Principal investigator of Korean Lung Cancer Screening Project (K-LUCAS)
- Principal investigator of development and revision of seven cancer screening guidelines in Korea

# Individualized Risk Prediction for Target Expansion of Lung Cancer Screening

**Yeol Kim, MD, MPH, PhD**National Cancer Center, Republic of Korea

Lung cancer is the cancer with the highest number of cases and deaths worldwide. Several randomized controlled trials conducted in America and Europe have reported that screening using low-dose chest CT to high-risk smokers can reduce lung cancer mortality. The National Lung Screening Trial (NLST) conducted in USA targeted high-risk groups having more than 30 pack year smoking history reported the effectiveness of lung cancer screening. Also the subsequent European studies targeting smokers with more than 15 to 20 pack years of smoking history also reported the effectiveness of lung cancer screening.

Based on these research results, the US preventive service task force (USPSTF) recommended that lung cancer screening, which was previously recommended for smokers with 30 pack-years or more, be expanded to people with a smoking history of 20 pack-years or more in March 2021. However, the USPSTF still does not recommend lung cancer screening using low-dose chest CT in low-risk groups without a smoking history. This is because the probability of early detection of lung cancer is low and the risk of harm from screening may increase.

In the current guidelines for lung cancer screening are based on age and smoking history. However, lung cancer risk prediction models that includes family history of lung cancer, history of lung disease, and exposure history to asbestos and radon in addition to smoking history can select more effective screening targets. Exposure to smoke from cooking in non-smoking women and exposure to fine dust related to air pollution are also suggested as risk factors for lung cancer, but it is difficult to measure individual exposure levels and their impact on lung cancer is not high compared to smoking. Therefore, further research is still needed to recommend expanding the scope of lung cancer screening.







Kai-Jen Chuang
Taipei Medical University

- Professor at Taipei Medical University
- Expert in environmental epidemiology
- Specializes in air pollution exposure assessment
- Conducted COVID-19 study on three-layer cotton masks
- Researches indoor air filtration and cardiopulmonary health
- Focuses on green energy micro-sensing devices for air pollution
- Engages in monitoring physiological indicators
- Prominent figure in the field of public health and environmental research





Anil Chaturvedi **Division of Cancer Epidemiology & Genetic, National Cancer Institute** 

#### **Affiliations**

 Senior Investigator, Clinical Genetics Branch, Division of Cancer Epidemiology & Genetic, National Cancer Institute

#### **Education**

- PhD, Epidemiology, Tulane University
- MS, Epidemiology, Tulane University
- BS, Veterinary Medicine, Andhra Pradesh Agricultural University

#### **Experience**

- Postdoctoral Fellow, Department of Biostatistics, University of Washington, 1991-1992
- Tenure-track investigator, Division of Cancer Epidemiology & Genetic, National Cancer Institute, 2009-2015
- Senior investigator, Division of Cancer Epidemiology & Genetic, National Cancer Institute, 2016
- Clinical Epidemiology Unit of the Clinical Genetics Branch, 2016-2020
- Senior Advisor for Faculty Development, Clinical Genetics Branch, Division of Cancer Epidemiology & Genetic, 2020-present



Ching-Yu Yen Chi Mei Medical Center

- Holds a Ph.D. from Taipei Medical University.
- Research expertise encompasses oral cancer surgical intervention and rehabilitation, early diagnosis of cancer-related pathological changes, and pioneering lymphocyte detection in oral cancer.







## Oral Cancer - Discussant

### Oral Cancer Screening in India



Prof. Malliga J Subramanian

Cancer Institute



Dr. Anil Chaturvedi
National Cancer Institute



Prof. Ching-Yu Yen
Chi Mei Medical Center

IACCS, Breast/Cervical /Lung /Oral Cancer
International Asian Cancer and Chronic Disease Screening Network, IACCS 2023



## Oral Cancer - Discussant

### **Oral Cancer Screening in Nepal**



Dr. Kishore Kumar Pradhananga Kathmandu Cancer Center Hospital



Dr. Anil Chaturvedi
National Cancer Institute



Prof. Ching-Yu Yen
Chi Mei Medical Center





Malliga J
Subramanian
Preventive Oncology Cancer
Institute (WIA)

- Internship at Dr. MGR Medical University, Chennai
- Resident in Obstetrics & Gynecology, Postgraduate MD Dr. MGR Medical University, Chennai
- Senior Registrar, Preventive Oncology, Tata Memorial Hospital, Mumbai
- Fellow, Gynecologic Oncology, Tata Memorial Hospital, Mumbai



Pardhananga
Kathmandu Cancer Center
Hospital, Tathali, Bhaktapur

#### Working Address

- Program Director, Kathmandu Cancer Center Hospital, Tathali, Bhaktapur
- Executive Chairman, Nepal Cancer Prevention and Screening Foundation, Kathamandu, Nepal

#### Academic Qualification

- Master of Public Health (MPH), National Institute of Preventive and Social Medicine (NIPSOM), Dhaka University, Dhaka, Bangladesh (1998)
- Doctor of Naturopathy & Yoga (NDYD) (1995), Gorakhapur School of Natural Therapeutics, Gorakhapur, India
- Diploma in Cancer Prevention and Control, National Cancer Institute, USA, (2004).

#### Working Experience

- Program Director, Kathmandu Cancer Center Hospital, Tathali, Bhaktapur (2019-untill now)
- B.P. Koirala Memorial Cancer Hospital (1995-2019)
- Designation- Head, Cancer Prevention, Control & Research Department, Bharatpur, Chitwan, Nepal (2008 -2017)







**Kelly Yu Preventive Oncology Cancer** Institute (WIA)

- Kelly J. Yu received a B.S. in biology from the University of Maryland, College Park, an M.P.H. from Yale University, and a Ph.D. from Johns Hopkins Bloomberg School of Public Health. She focused her doctoral dissertation on evaluating early risk factors and prevention of nasopharyngeal carcinoma in high-risk families and continued her postdoctoral work in the same area under the mentorship of Allan Hildesheim, Ph.D. In January 2011, she joined the Early Detection Research Group in the Division of Cancer Prevention as an epidemiologist and project officer for the Prostate, Lung, Colorectal, and Ovarian Screening Trial. She returned to DCEG/IIB in November 2015 as a staff scientist and was appointed as Branch Assistant Director in 2021.
  - Dr. Yu has received several awards for her research, including the AACR Scholar-in-Training Award and the NCI Award of Merit.







## DEC 15-16, 2023

TOKYO, JAPAN Hotel Villa Fontaine Grand Tokyo-Ariake



## **Precision Cancer Screening** with Al Perspectives

International Asian Cancer and Chronic Disease Screening Network https://www.iaccs.asia/



















































